Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response
暂无分享,去创建一个
[1] D. Olive,et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. , 2007, Blood.
[2] J. Armitage. How I treat patients with diffuse large B-cell lymphoma. , 2007, Blood.
[3] T. Rebbeck,et al. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. , 2007, Blood.
[4] T. Lister,et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. , 2007, Cancer research.
[5] Michael B Yaffe,et al. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.
[6] A. Wiestner,et al. Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines , 2006, Clinical Cancer Research.
[7] K. Anderson,et al. Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib * , 2006, British journal of haematology.
[8] A. Nudelman,et al. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. , 2006, Cancer research.
[9] Gouri Nanjangud,et al. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. , 2006, Blood.
[10] I. Lossos,et al. Prognostic biomarkers in diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Al-Kuraya,et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. , 2005, Blood.
[12] L. Staudt,et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. , 2005, Blood.
[13] Y. Yatabe,et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. , 2005, Cancer research.
[14] Mi Ae Kim,et al. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype , 2005, Oncogene.
[15] S. Lowe,et al. A microRNA polycistron as a potential human oncogene , 2005, Nature.
[16] Masakazu Toi,et al. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.
[17] S. Horvath,et al. Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases , 2005, Clinical Cancer Research.
[18] A. Olshen,et al. Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells , 2005, Functional & Integrative Genomics.
[19] S. Lees-Miller,et al. Doxorubicin Activates ATM-dependent Phosphorylation of Multiple Downstream Targets in Part through the Generation of Reactive Oxygen Species* , 2004, Journal of Biological Chemistry.
[20] T. Golub,et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.
[21] J. Kobarg,et al. Detection and Possible Prognostic Relevance of p53 Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature , 2004, Leukemia & lymphoma.
[22] Nallasivam Palanisamy,et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. , 2004, Blood.
[23] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[24] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[26] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.
[27] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[28] Robert Tibshirani,et al. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. , 2003, Blood.
[29] Alexander L. Dent,et al. Repression of AP-1 Function: A Mechanism for the Regulation of Blimp-1 Expression and B Lymphocyte Differentiation by the B Cell Lymphoma-6 Protooncogene1 , 2002, The Journal of Immunology.
[30] John D. Storey. A direct approach to false discovery rates , 2002 .
[31] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[32] S. Heath,et al. Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[33] N. Munshi,et al. NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.
[34] M. Minden,et al. Molecular cytogenetic characterization of non‐Hodgkin lymphoma cell lines , 2002, Genes, chromosomes & cancer.
[35] S. Barrans,et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.
[36] D. Weisenburger,et al. Similar patterns of genomic alterations characterize primary mediastinal large‐B‐cell lymphoma and diffuse large‐B‐cell lymphoma , 2002, Genes, chromosomes & cancer.
[37] P. Vyas,et al. Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .
[38] A. Iavarone,et al. Id proteins at the cross-road of development and cancer , 2001, Oncogene.
[39] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[40] N. Magné,et al. Activation of Nuclear Factor κB through the IKK Complex by the Topoisomerase Poisons SN38 and Doxorubicin: A Brake to Apoptosis in HeLa Human Carcinoma Cells , 2001 .
[41] E. Schattner,et al. Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells1 , 2000, The Journal of Immunology.
[42] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[43] Ahmed Mansouri,et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix–loop–helix inhibitor Id2 , 1999, Nature.
[44] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Cigudosa,et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. , 1998, Blood.
[46] V. Reuter,et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation , 1998, Oncogene.
[47] M. Minden,et al. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. , 1995, Leukemia & lymphoma.
[48] D. Scudiero,et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.
[49] E. Suzuki,et al. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis , 2007, Oncogene.
[50] 林下 陽二. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation , 2006 .
[51] L. Staudt,et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] K. Savage,et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. , 2005, Blood.
[53] M. Toi,et al. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.
[54] L. Staudt,et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .
[55] Emili Montserrat,et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.
[56] N. Munshi,et al. NF-kappa B as a therapeutic target in multiple myeloma. , 2002, The Journal of biological chemistry.
[57] N. Magné,et al. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. , 2001, Cancer research.
[58] E. Schattner,et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. , 2000, Journal of immunology.